Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutikizumab and Ravagalimab in Rheumatoid Arthritis
NCT06972446Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2025
- Primary completion
- Feb 2027
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of lutikizumab, ravagalimab in rheumatoid arthritis (RA), sponsored by AbbVie Inc.. Started Jun 2025; status: recruiting.
02
Drugs
lutikizumabravagalimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06972446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06972446.